The present invention provides the use of a glutamine derivative in preparing animal feed additives, and particularly the use of a glutamine derivative having a structure of formula (I), a racemate thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a solvate thereof, or a feed acceptable salt thereof. Animal breeding experiments revealed that, the provided compounds, including the glutamine derivative, the racemate thereof, the stereoisomer thereof, the geometric isomer thereof, the tautomer thereof, the solvate thereof, and the feed acceptable salt thereof, can be used as animal feed additives, exhibiting excellent effect in improving animal production performance such as growth and feed efficiency.

##STR00001##

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

The invention relates to a compound of general formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.

The invention relates to a compound of general formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.

The invention relates to a compound of general formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl-3 and are useful for the treatment of cancer, particularly metastatic cancer.

The invention relates to a compound of general formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl-3 and are useful for the treatment of cancer, particularly metastatic cancer.

The present invention provides cystobactamides of formula (I): R.sup.1—Ar.sup.1-L.sup.1-Ar.sup.2-L.sup.2-Ar.sup.3-L.sup.3-Ar.sup.4-L.sup.4-Ar.sup.5—R.sup.2 and the use thereof for the treatment or prophylaxis of bacterial infections.

The present invention provides cystobactamides of formula (I): R.sup.1—Ar.sup.1-L.sup.1-Ar.sup.2-L.sup.2-Ar.sup.3-L.sup.3-Ar.sup.4-L.sup.4-Ar.sup.5—R.sup.2 and the use thereof for the treatment or prophylaxis of bacterial infections.

Provided are aromatic oligoamide foldamers and self-assembled compositions of the same. The aromatic oligoamide foldamers and compositions can form tube-like structures that can form pores in membranes. The pores can be used to transport ions and molecules, such as, for example, cryoprotective agents or therapeutic agents, through the membrane. The tube-like structures exhibit desirable stability at low temperatures.